Accordingly, we analyzed the mechanism of CAT in cerebral ischemic via the NRF1/KAT2A/METTL3/Beclin-1 axis with the focus on neuronal injury and autophagy, aiming to offer a theoretical basis for the development of CAT as neuroprotective drugs for the prevention and treatment of cerebral ischemia. The gene discussed is KAT2A; the disease is brain ischemia.